Navigation Links
FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD
Date:6/1/2009

ADHD symptom control demonstrated from the first time point measured (1.5 hours) through 13 hours postdose

PHILADELPHIA, June 1 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) has approved a change to the prescribing information for its once-daily Attention Deficit Hyperactivity Disorder (ADHD) treatment VYVANSE(R) (lisdexamfetamine dimesylate) CII, to include supplemental data that demonstrated significant ADHD symptom control in children aged 6 to 12 from the first time point measured (1.5 hours) through 13 hours postdose. VYVANSE is now the first and only oral ADHD stimulant treatment to have 13-hour postdose efficacy data for pediatric patients included in its product labeling.

"Children with ADHD who still exhibit symptoms into the evening might need a treatment that provides a long duration of effect from morning, through homework and family time," said Michael Yasick, Senior Vice President of the ADHD Business Unit at Shire. "The FDA approval of this labeling change for VYVANSE provides important additional information for physicians on the duration of effect of VYVANSE and use as a once daily treatment option."

This update to the VYVANSE product labeling is based on a 13-hour analog classroom study that demonstrated improvements in behavior, inattention, and math test scores in children aged 6 to 12 from the first time point measured (1.5 hours) through the last time point assessed (13 hours) postdose. This study supports the results of a previous Phase 2 laboratory school study in which VYVANSE demonstrated ADHD symptom control from the first time point assessed (two hours postdose) with duration of efficacy up to 12 hours postdose. The adverse events in the 12-h
'/>"/>

SOURCE Shire plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. FDA Approves Boston Scientifics Next-Generation TAXUS(R) Liberte(R) Atom(TM) Stent System
2. Arpida Annual General Meeting of Shareholders Approves All Board Proposals
3. Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
4. FDA Approves Label Change for Non-Invasive Fibroid Treatment
5. FDA Approves SyntheMeds REPEL-CV(R) Adhesion Barrier for Use in Pediatric Cardiac Surgery
6. FDA Approves SYMBICORT(R) for Chronic Obstructive Pulmonary Disease (COPD)
7. FDA Approves Apidra(R) SoloSTAR(R) - a Prefilled Disposable Insulin Pen
8. European Commission Approves EFIENT(R) (prasugrel) for Patients with Acute Coronary Syndrome Undergoing PCI
9. Encouraging high-risk research: DFG approves funding for 2 new Reinhart Koselleck projects
10. FDA Approves ULORIC(R) (febuxostat) for the Chronic Management of Hyperuricemia in Patients with Gout
11. FDA Approves Clinical Studies of a Novel Anti-Cancer Drug Developed by Italian Researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... Balaton, MN (PRWEB) April 27, 2015 ... into an agreement with Texas A&M University for the ... referred to as super-intensive raceway systems. The license agreement ... Dr. Addison Lawrence, extends to countries such as China, ... United Kingdom. , “We have had inquires from ...
(Date:4/27/2015)... Diasome Pharmaceuticals, Inc. (“Diasome”) has announced ... Center (“Joslin”) to collaborate on the design of ... Directed Vesicle (“HDV”) targeting system for insulin in ... in Boston, Massachusetts, Joslin is the world's leading ... to the prevention, treatment and cure of diabetes. ...
(Date:4/27/2015)... -- Together with its customers, Elekta raised EUR 30,575 (USD ... Barcelona . The funds will be donated to ... improve cancer care, specifically radiation oncology care, around the ... should be denied potentially life-saving treatment simply because the ... and clinics around the world to take care of ...
(Date:4/27/2015)... 2015 Elsevier , a world-leading ... and Qatar University Research Office   have announced the winners ... The awards ceremony, held last week at Qatar ... by more than 40 guests representing Qatar,s ... Professor Sheikha Abdulla Al-Misnad , President of ...
Breaking Biology Technology:tru Shrimp™ Systems Acquires Global Patent for Tidal Basin™ Shrimp Production 2Diasome Pharmaceuticals Announces Clinical Trial Design Collaboration 2Elekta helps raise $33,000 to bring radiation treatment to developing countries 2Elekta helps raise $33,000 to bring radiation treatment to developing countries 3Elsevier Announces the Winners of Qatar University Scientists 2015 Scopus Awards 2Elsevier Announces the Winners of Qatar University Scientists 2015 Scopus Awards 3Elsevier Announces the Winners of Qatar University Scientists 2015 Scopus Awards 4Elsevier Announces the Winners of Qatar University Scientists 2015 Scopus Awards 5
... Nov. 29 As part of an ongoing ... maximize commercial,impact of their products, Premier Research Group ... industry-leading expertise in its core,service areas into a ... expertise within the group closely matches Premier Research,s ...
... Multi-stakeholder initiative will use health information technology ... safety efforts across,the U.S., WASHINGTON, Nov. ... announced today the formation of an innovative,research ... patients. The eHI,Connecting Communities for Drug Safety ...
... Prometheus Laboratories Inc., a,specialty pharmaceutical company ... exclusive license agreement to develop and commercialize ... North America from,Alizyme Therapeutics Limited, a wholly ... unique competitive profile based on Alizyme,s proprietary,COLAL(R) ...
Cached Biology Technology:Product Development Timelines and Commercialization Strategy Are Focus of New Group at Premier Research 2eHealth Initiative Foundation Launches Collaborative Research Effort to Improve Drug Safety 2eHealth Initiative Foundation Launches Collaborative Research Effort to Improve Drug Safety 3eHealth Initiative Foundation Launches Collaborative Research Effort to Improve Drug Safety 4eHealth Initiative Foundation Launches Collaborative Research Effort to Improve Drug Safety 5eHealth Initiative Foundation Launches Collaborative Research Effort to Improve Drug Safety 6Prometheus Licenses COLAL-PRED(R) From Alizyme 2Prometheus Licenses COLAL-PRED(R) From Alizyme 3Prometheus Licenses COLAL-PRED(R) From Alizyme 4
(Date:3/20/2015)... 20, 2015 Research and Markets ... the "India Sensors Market Forecast and Opportunities ... The sensor market is projected to grow at ... Consumer electronics, automotive, industrial and healthcare sectors are ... country. In addition, adoption of MEMS technology in ...
(Date:3/20/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) has announced ... Business Report" report to their offering. This ... Thousands. The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... America . Annual estimates and forecasts are ...
(Date:3/17/2015)... 2015 MedNet Solutions , a ... study management systems, is pleased to announce that ... Outsourcing in Clinical Trials Southeast conference – March ... excellent forum for MedNet to showcase iMedNet ... (SaaS) eClinical technology platform. We strongly ...
Breaking Biology News(10 mins):India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2
... of Toronto and the Swiss Federal Institute of Technology ... exotic plants will likely eliminate native plants growing in ... A study published in Proceedings of the National ... that invasive plants are not problematic are often based ...
... January 2013) The microbial communities that reside in the ... are an expanding area of research full of exciting discoveries ... on the most recent advances in the field, scientists and ... For Health World Summit, which is hosted this year by ...
... changed diabetes from a death sentence to a chronic ... Case Western Reserve University School of Medicine announced a ... lives of people managing diabetes. After decades of ... international group of scientists finally found a definitive answer: ...
Cached Biology News:Invading species can extinguish native plants despite recent reports 2After decades of research, scientists unlock how insulin interacts with cells 2After decades of research, scientists unlock how insulin interacts with cells 3
IgD Chain C (AMS 9.1)...
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Applications: Epitope mapping, Mapping protein-protein contacts, Identification of enzyme substrates/inhibitors, Identification of receptor agonists/antagonists...
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Biology Products: